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Abstract

Background and Purpose: Refinement of robotic exoskeletons for overground walking is progressing rapidly.
We describe clinicians' experiences, evaluations, and training strategies using robotic exoskeletons in spinal
cord injury rehabilitation and wellness settings and describe clinicians' perceptions of exoskeleton benefits
and risks and developments that would enhance utility.
Methods: We convened focus groups at 4 spinal cord injury model system centers. A court reporter took
verbatim notes and provided a transcript. Research staff used a thematic coding approach to summarize
discussions.
Results: Thirty clinicians participated in focus groups. They reported using exoskeletons primarily in
outpatient and wellness settings; 1 center used exoskeletons during inpatient rehabilitation. A typical episode
of outpatient exoskeleton therapy comprises 20 to 30 sessions and at least 2 staff members are involved in
each session. Treatment focuses on standing, stepping, and gait training; therapists measure progress with
standardized assessments. Beyond improved gait, participants attributed physiological, psychological, and
social benefits to exoskeleton use. Potential risks included falls, skin irritation, and disappointed expectations.
Participants identified enhancements that would be of value including greater durability and adjustability,
lighter weight, 1-hand controls, ability to navigate stairs and uneven surfaces, and ability to balance without
upper extremity support.
Discussion and Conclusions: Each spinal cord injury model system center had shared and distinct practices in
terms of how it integrates robotic exoskeletons into physical therapy services. There is currently little
evidence to guide integration of exoskeletons into rehabilitation therapy services and a pressing need to
generate evidence to guide practice and to inform patients' expectations as more devices enter the market.
Video Abstract available for more insights from the authors (see Video, Supplemental Digital Content 1, available
at:http://links.lww.com/JNPT/A231).

INTRODUCTION

The impairment or loss of the ability to stand and walk following spinal cord injury (SCI) results in significant
health consequences, not only limiting mobility and performance of activities of daily living but also limiting
functional recovery and increasing the risk for secondary complications. Secondary complications include
pressure injuries, increased spasticity, limited joint range of motion, contractures, muscle disuse or reduced
use atrophy, reduced bone density, increased pain (both neuropathic and musculoskeletal), depression, and
impaired digestive, respiratory, renal, and cardiovascular function.1 Even for individuals with motor
incomplete SCI who are able to walk, walking is generally slow, labored, uncoordinated, and variable.2 With
intensive training, walking function sometimes can be improved, but walking speed may remain slower than
that required for community ambulation.3 Thus, many individuals who have some motor function below their
lesion level use a wheelchair as their primary mode of mobility. Thus, there exists a need for better
therapeutic and mobility training devices.

Potential Benefits and Limitations of Robotic Exoskeletons

Overground robotic exoskeletons offer potential therapeutic benefits while providing intense overground
stepping practice and, compared with some approaches, may require fewer therapists to provide assistance
for stepping and stability during training in individuals with very limited stepping function. Other benefits of
exoskeleton use reported in the literature include improved posture and reduced spasticity and reduced
complications affecting cardiovascular, gastrointestinal, and renal systems.4,5 Standing may provide
psychological benefits as well.6 Exoskeletons thus may provide an alternative strategy to realize the same
benefits associated with other mobility training strategies.7
Currently, however, most studies have been limited to evaluation of the safety and efficacy of robotic
exoskeletons for individuals with SCI using the 3 main commercially available exoskeletons (Ekso, ReWalk, and
Indego).8 Specifically, using the Indego exoskeleton,9 individuals with paraplegia transitioned to limited
community ambulation after five, 1.5-h gait-training sessions.9 The Indego required less effort than a
standard locked knee-ankle-foot orthoses, and participants performed strength and endurance tests 25% to
75% faster.10 In a small, prospective study involving 8 individuals with SCI at the T1 level and below, the Ekso
exoskeleton was used safely for overground walking when monitored by a therapist.11 In an another case
series of 3 individuals with complete SCI, participants achieved walking speeds and distances comparable with
persons with motor incomplete injuries, although there were no changes in volitional leg muscle activation or
cortical activity and negligible improvement in metabolic efficiency.12 Similar safety and efficacy studies exist
for the ReWalk exoskeleton.13-16

Potential Benefits of Robotic Exoskeletons: Health Care Providers and Therapists

Exoskeletons have the potential to decrease burden on therapists during overground walking, while
encouraging high intensity and dosage with less fatigue compared with traditional therapy. Thus, they could
reduce personnel costs to the health system, while potentially achieving similar functional and health
outcomes. In contrast to treadmill, robot-based approaches, exoskeletons enable overground mobility in
home and wellness settings for individuals who may not achieve this level of function with conventional
therapy. However, these devices are still in their early days of development, lack strong evidence for clinical
and cost effectiveness, and providers are exploring optimal ways of tapping the clinical and financial viabilities
of these technologies.

Given the rapid development and deployment of exoskeletons and the costs of rehabilitation, it is essential to
learn from early adopters of robotic exoskeletons. Thus, this study obtained clinician input on the usability
and applications of exoskeletons as part of rehabilitation services for adults with SCI (Tables 1 and 2). The aim of
the study was to describe clinicians' experiences, evaluations, and training strategies using exoskeletons in
rehabilitation and wellness settings. This study addresses 3 primary questions:
Table 1. Robotic Exoskeletons Marketed for Rehabilitation
Device
Manufacturer

FDA
Approval

Description

ReWalk (ReWalk
Robotics, Inc)

Therapy for
personal
mobility

Indego (Parker
Hannifin
Corporation)

Therapy for
personal
mobility

Ekso (Ekso
Bionics)

Therapy

Independently controlled bilateral hip and knee joint motors, a
rigid pelvic frame that links both lower limbs, ankles comprise
double action orthotic joints with limited motion and
adjustable spring-assisted dorsiflexion
Consists of 3 devices (small, medium, and large) including a hip
segment and right and left thigh and shank segments.17 Four
motors, 1 at each hip and knee joint, power movement, and
built-in ankle-foot-orthoses support the ankles9
Purchase price includes therapy kit, software suite, 3-d clinical
training on-site, and storage unit
Incorporates hip and knee motors; adjustable, spring-assisted
ankles with dorsiflexion/plantarflexion support assistance;
variable/adjustable swing assistance; adjustable stance support
and free trajectory assist; and femoral and tibial shanks
support body weight

Approximate
Purchase
Cost
$75 000

$189 670

$125 000

Abbreviation: FDA, Food and Drug Administration

Table 2. Manufacturers’ Guidelines for Robotic Exoskeleton Candidate Selection
Manufacturers’ Guideline
Physician clearance
required
Standing program needed
Weight limit
Height limit
Leg length discrepancy
Standing hip width
ROM

EKSO
Yes

ReWalk
Yes

Indego
Yes

Yes
<100 kg
152-193 cm
Upper leg: <1.3 cm N/A
Lower leg: <1.9 cm
≤45.7 cm

Yes
<100 kg
152-193 cm
Femur range: 36-48.5 cm
Tibia range: 43.5-56 cm
29-37 cm

Yes
<113 kg
155-191 cm
Femur length: 35.6-47 cm

Hip: ≤17◦
Knee: ≤12◦
Neutral ankle dorsiflexion

Sufficient LE ROM to allow
ambulation

Sufficient shoulder, hip,
knee, and ankle ROM, with
functional limits for walking
with a stability aid

≤42.2 cm seated

SCI level and
completeness
therapy ambulation T4-L5
therapy ambulation
Contraindications

T4-L5
C7-T3 ASIA D T4-T6
•

•
•

•
•

•
•
•
•

•
•

•
•
•
•

•
•
•

ROM restrictions
that would prevent
a patient from
achieving a normal,
reciprocal gait
pattern, or would
restrict a patient
from completing
normal sit-to-stand
or stand-to-sit
transitions
Spinal instability (or
spinal orthotics
unless cleared
by a medical doctor)
Unresolved DVT
Subcutaneous
cranial bone flap
stored in abdomen
Decreased standing
tolerance due to
orthostatic
hypotension
Significant
osteoporosis that
prevents safe
standing
or may increase the
risk of fracture
caused by
standing or walking
Uncontrolled
spasticity
Uncontrolled
autonomic
dysreflexia
Skin integrity issues
on contact surfaces
of the device
or that would
prohibit sitting
Pregnancy

T7-L5 community
ambulation
T4-T6 therapy ambulation
•
•
•
•
•
•
•
•
•

Uncontrolled
spasticity or clonus
Fractures
Infection
Pressure injury
DVT
Severe concurrent
medical conditions
Psychiatric or
cognitive issues
Pregnancy
Lactation

T7-L5 community
ambulation
T4-L5 therapy ambulation
•

•
•
•
•
•
•
•

•
•
•

•
•
•
•

Severe spasticity
(Modified
Ashworth 3)
Heterotopic
ossification
Skin integrity issues
Upper extremity
strength deficits
Spinal instability
Spinal orthotics
Unresolved DVT
Diminished
standing tolerance
due to orthostatic
hypotension
Osteoporosis
ROM restrictions
Uncontrolled
autonomic
dysreflexia
Colostomy
Lower limb
prosthesis
Cognitive
impairments
Pregnancy or
planning to be
pregnant

1. What are clinicians' experiences, clinical evaluations, and training strategies using robotic exoskeletons in
rehabilitation and wellness settings?
2. What benefits and risks of exoskeletons do clinicians perceive?
3. What limitations of exoskeletons do clinicians identify, and what changes do they suggest for hardware and
software development?

METHODS
Sample

This study used qualitative methods to address the questions by organizing focus groups at 4 SCI model
systems (SCIMS): (1) Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago), (2) Craig
Hospital, (3) Shepherd Center, and (4) TIRR Memorial Hermann. These centers chose to participate in the
AbilityLab's collaborative module during the current SCIMS funding cycle. The focus groups occurred between
February and April 2017, comprising primarily physical therapists with experience using robotic exoskeletons.
Clinicians provided informed consent and received a modest honorarium.

Procedures

Collaborators developed a discussion guide, which the moderator used for all focus groups (see the Appendix).
The moderator led the AbilityLab focus group in person and used videoconferencing technology to lead focus
groups at the other 3 centers. A court reporter took verbatim notes and provided a transcript of the
discussion. Research staff members took notes to supplement transcript reviews, which provided the basis for
qualitative coding and analysis.

Data Analysis

We adopted a thematic coding approach 18 to summarize clinicians' responses to questions regarding
patients' motivations for exoskeleton use and their perceived risks and benefits of exoskeleton use; most
questions did not require qualitative coding as they focused on details regarding settings in which
exoskeletons are used, eligibility criteria, assessment protocols, and other therapy procedures. For questions
requiring qualitative coding, the procedures involved developing a codebook, testing the reliability of codes,
summarizing data and identifying initial themes, applying code templates, connecting codes and themes, and
corroborating and legitimating coded themes. Center principal investigators and coordinators participated in
codebook development and transcript coding. They resolved coding discrepancies by discussing their different
perspectives and reaching code consensus. Northwestern University's and Shepherd Center's institutional
review boards approved the protocol.

Table 3. Focus Group Participant Demographic Characteristics

Demographic Characteristic

Craig Hospital
(n = 5)

Shepherd Center
(n = 10)

TIRR Memorial
Hermann
(n = 11)
33 (29-46)
9 (2-22)
0

Total (n = 30)

40 (28-53)
13 (4-30)
14 (3-25)

Shirley Ryan
AbilityLab
(n = 4)
34 (30-40)
5 (3-6)
0

Age (median years, range)
Clinical experience (median years, range)
Other experience (median years, range)
Sex
Female
Race
White
Asian/Indian
Multiracial
Missing
Hispanic
Yes
No
Missing
Role
Physical therapist
Administrative
Other clinical role (exercise therapist,

42 (33-48)
9 (3-20)
0
100%

80%

75%

91%

86%

60%
0%
40%
0%

90%
0%
0%
10%

100%
0%
0%
0%

82%
9%
0%
9%

83%
2%
10%
5%

20%
80%
0%

0%
90%
10%

0%
100%
0%

0%
91%
9%

5%
90%
5%

100%
0%
0%

60%
10%
30%

100%
0%
0%

100%
0%
0%

90%
2%
8%

37 (28-53)
9 (2-30)
14 (3-25)

RESULTS
Sample Characteristics

Table 3 summarizes the characteristics of the 30 focus group participants. The sample represents nearly all

therapists trained in exoskeleton use, although a few did not participate because of illness or schedule
conflicts. They were predominantly female and white and had an average of 10 years of clinical experience.
Most were physical therapists but included other clinical and support staff members with training and
experience in the use of robotic exoskeletons.

Focus Group Data

We organize focus group data under 3 topics: (1) exoskeleton experience, clinical evaluations, and training
strategies, (2) exoskeleton benefits and risks, and (3) exoskeleton preferences. Two investigators read the
transcript from each of the 4 focus groups, highlighted text relevant to patients' motivation for seeking
therapy incorporating exoskeletons and clinicians' perceptions of risks and benefits. Thematic code
development was straightforward, given the finite range of responses and consistency of responses across
centers. Coders achieved consensus by discussing the instances for which they initially assigned discrepant
codes. Investigators did not code responses to questions focused on procedural details of therapy involving
exoskeletons, given the fact-focused nature of the questions.

Topic 1: Exoskeleton Experience, Clinical Evaluations, and Training Strategies

Topic 1 included several subtopics, perceived benefits and risks of exoskeletons pertaining to therapists'
experiences, clinical evaluations, and training strategies. Table 4 summarizes the therapists' answers to the
discussion questions at each center. The "topic column" represents the questions posed to each of the
groups. The table's cells contain bulleted lists summarizing the discussion.

Table 4. Summary of Robotic Exoskeleton Experience at 4 SCI Model System Centers
Topic

Craig Hospital

In what
settings do
you provide
robotic
exoskeleton
therapy?

•

How do you
use robotic
exoskeleton
s
in your
practice?

•

•

•

Shepherd Center

Wellness
program
(private pay)
Research

•
•

Basic skills
training
(includes
transfers,
manual joint
adjustment,
don/doff,
standing
balance, sit
to/from stand,
com icator
use, 10 MWT
0.15 m/s,
turning R/L18
l collapse, byp
edge, wall
rest)
Advanced
skills training
(includes
walkie-talkie,
walking in
busy
environment,
reading, door
navigation,
timed
automatic
door
navigation,
bench sit
to/from stand,
timed walking
at crosswalk,
ramps, side
angle walking,
multiple
surface such
as tile, carpet,
asphalt, 10
MWT ≥0.4
m/s, 6MWT ≥
utouts

•

•
•

•
•
•

Outpatient
Research
(ReWalk,
Indego)
Wellness
Program
(private pay)
Weight
bearing
Balance
Gait training
Cardiovascula
r health

Shirley Ryan AbilityLab
(RIC)
• Outpatient
• Research

•
•
•

Mobility
Retraining
Gait traini

TIRR Memorial
Hermann
• Inpatient
• Outpatient
• Home use
(private pay)
• Research

•
•
•

As a
modality to
promote
neurorecove
ry
Gait training

What
criteria do
you use to
select
patients
with SCI for
robotic
exoskeleton
s?

•
•

•

•

What goals
do patients
pursue with
a robotic
exoskeleton
?

•
•

Manufacturer’
s criteria
Functional
level; use
Indego for
patients with
more
function, Ekso
for patients
with less
function
Resources to
purchase
device

•

Personal use
training
Health and
wellness

•

•

•
•

Manufacturer’
s criteria
Lower
extremity
function
Recovery
Personal use

•
•
•
•
•

Manufacturer’s
criteria
Motivation
Confidence
Cognitive ability
Seeking mobility
options

•
•

•
•
•

•

•
•

Personal use
training
Health and
wellness
Gait training

•
•
•

Personal use
training
 Standing upright
 Gait training

•
•
•
•
•
•

What
motivates
patients to
try a
robotic
exoskeleto
n?

•
•
•
•

•

What
devices are
you using?

Exercise
Walking
Standing
upright
Improved
bowel and
bladder
function
Reduced
spasticity

Indego
Ekso
ReWalk

•
•
•

•
•

•
•

Exercise
Walking
Opportunity
to try
something
new
Standing
Balance
Strengthenin
g core and
peripheral
muscles
Indego
ReWalk

•
•

•

•
•
•

Family
encouragement
Opportunity to
try something
new
Increase
strength

•
•

Indego
Ekso
ReWalk

•

•

•
•

How many
sessions
comprise a
typical
episode of
robotic
exoskeleto
n therapy?

•
•

Outpatient
typically 6-8
Personal use
up to 16

•

Variable:
Depends on
insurance
and personal
resources

•
•
•

Manufacturer
’s criteria
Ability to
follow
commands
Tolerate
being upright
Secondary
health
benefits
No
contraindicati
ons
Patient goals

Personal use
training
Standing and
stepping
Gait training
Self-control
Spasticity
Neurorecove
ry
Walking
Upright
standing
(eye-to-eye
contact)
Increase
strength

Indego and
Ekso for
research
Ekso for
inpatient
ReWalk for
outpatient
Inpatient: 6
sessions, 1-h
duration
Outpatient:
15-20 for
ReWalk
Outpatient:
30 for
independent

How many
staff
members
are
involved in
a therapy
session
using a
robotic
exoskeleto
n?

•
•

1 PT and 1
aide/caregiv
er
Varies
depending
on functional
ability of
client

•

•

•

What
benefits do
patients
experience
in using a
robotic
exoskeleto
n?

•
•
•
•
•
•
•

Standing
upright
Weight
bearing
Cardiovascul
ar
Reduced
pain
Bowel/bladd
er benefits
Reduced
spasticity
Sense of
well-being

•
•
•
•
•
•
•
•
•
•
•

What risks
might
patients
experience
in using a
robotic

•

Disappointm
ent of
expectations
(eg, not able
to transport
device, still

•
•
•
•

1 PT and
exercise
specialist for
initial setup
in wellness
program
1 exercise
specialist
and 1
aide/caregiv
er for
training in
wellness
program
1 PT and 1
aide for
evaluation
and training
in outpatient
program
Increased
trunk
strength
Improved
function
Reduced
pain
Reduced
spasticity
Reduced
medication
use
Increased
strength
Improved
ASIA scores
Improved
confidence
Psychosocial
benefits
More steps
Reduced
UTIs
Falls
Fractures
Skin
breakdown
Disappointm
ent of
expectations

•

1 PT and 1
aide/caregiver

•

1 PT and 1
aide

•
•
•

Standing upright
Weight bearing
Improved
confidence
Psychosocial
benefits
Improved
function
More steps

•

Standing
upright _
Bowel/bladd
er function
Gait
Trunk
strength
Reduced
pain
Reduced
spasticity
Increased
strength
Increased
endurance
Reduced
need for
assistance
Psychosocial
benefits

•
•
•

•
•
•
•
•
•
•
•

•
•

Falls
Skin breakdown

•
•

Fracture
risks
Skin
breakdown

exoskeleto
n?
Do you use
any
standardize
d
assessment
s to
monitor
progress in
robotic
exoskeleto
n therapy?

•
•
•
•
•
•
•
•
•
•
•

Have
patients
purchased
a robotic
exoskeleto
n?
What
robotic
exoskeleto
n features
would you
like to see
added?

need
caregiver)
10-m walk
6-minute
walk test
Trunk
assessment
Berg Balance
Scale
Document
time up and
walking
Timed Up
and Go
Don and doff
time
Step count
Rate of
Perceived
Exertion
FIM walking
rating
Skills
inventory for
ReWalk

•
•
•
•
•
•
•
•

•
•
•

•

ReWalk (1)

•

•

FES
integrated in
exoskeleton
Reduce fall
risk
Lighter
weight
Greater
durability
One hand
free
Adjustable
ankles

•

•
•
•
•
•

•
•
•
•

10-m walk
test
6-minute
walk test
Trunk
assessment
Berg Balance
Scale
Cardiovascul
ar testing
Range of
motion
Skin
assessment
Spinal cord
assessment
tool for
spastic
reflexes
Goals
ASIA
Impairment
Scale
Manual
muscle
testing
Indego (2)

•
•

10-m walk test
6-minute walk
test
Berg Balance
Scale
Function in
Sitting Test
Functional gait
assessment
Five Times Sit to
Stand Test
Metabolic
assessment
Informal patient
report

•
•

•

In process

•

ReWalk
Personal 6
(1)

FES
integrated in
exoskeleton
Selfbalancing
capacity
Dynamic
ankle joint
Powered
ankle joint
Capacity to
ascend and
descend
stairs

•
•

Better fit
Adjustable for
more body
types
Lighter weight
Accommodation
of
thoracolumbosa
cral orthosis or
colostomy

•

FES
integrated in
exoskeleton
Better fit
Lighter
weight
More
intuitive
user
interface
(battery
level, ease,
and clarity of
changing
modes),
greater

•
•
•
•
•
•

•
•

•

•
•
•
•

10-m walk
6-minute
walk test
Trunk
assessment

modular
design,
ability to
modify
•
parameters
to adapt to
the
environment
•
• Capacity to
ascend and
descend
stairs
• Capacity to
navigate
uneven
surfaces
• Ability to
step
backwards
• Silent
motors
• Voice
recognition
feature
• Dynamic
standing
option
• Improved
rehabilitatio
n unit
support of
distal lower
extremity
(similar to a
personal
unit)
• Decreased
friction of
lower
extremity
• Cuffs over
fibular head
Abbreviations: ASIA D, American Spinal Injury Association D; FES, Functional Electrical Stimulation; FIM,
Functional Independence Measure; MWT, Meter Walk Test; PT, physical therapist; RIC, Rehabilitation Institute
of Chicago; SCI, spinal cord injury; UTIs, Urinary Tract Infection.
•

Therapy flex
mode for
Indego
Capacity to
ascend and
descend
stairs
Capacity to
navigate
uneven
surfaces

Participants reported using exoskeletons for various clinical and research applications. All used exoskeletons
in outpatient settings and community wellness facilities, with 1 center (TIRR) reporting selective use during
inpatient rehabilitation. All SCIMS centers followed device manufacturers' patient selection criteria faithfully.
Clinicians commented on the lack of guidance available regarding the integration of exoskeletons into
rehabilitation therapy services. One clinician stated:
When we were going through the training with devices we pulled some folks from inpatient, some of
our other programs ... in order for us to get experience, but we are still trying to kind of figure out
how, from an outpatient perspective, we are going to be utilizing the devices ... on a more regular
basis in our centers. So really the main experience that ... [we had] are just folks who have ... decided
to purchase a device, and ... are using their insurance benefits to come ... for training.
Another therapist elaborated on the limited evidence base:
This is a new device for us, and so we are being very systematic about what are we doing with the
decision[s] we are making, so that people feel like they have support for the decisions that they may
be making as an individual.... We have started in the key area of outpatient because that was a little
cleaner, and we also ... had people that were ready to go and willing to get their personal devices.
Clinicians emphasized the importance of screening candidates thoroughly to avoid adverse consequences:
I think out in the community people are going to fall, and they probably will injure themselves, and
whether you have 6 pounds on top of you if you are walking in of them versus 26 pounds, I think
there is risks for injury, for fracture, for ... bone fractures or skin injury. But I think the key to that in
reducing that is proper screening and the training that goes behind it the screening process and the
education is really important to reduce those risks.
Another focus group participant emphasized discussing patients' expectations during screening, considering
not only physiological and functional characteristics but also psychosocial characteristics. A clinician
commented:
...screening for personal use aspect, I think what it really boils down to is us just being able to have open and
honest conversation. It's not necessarily trying to discourage anybody from buying a device that they want,
but ... asking them.... 'Realistically, what are your expectations? What do you expect to be able to do in this?
And then, letting them know whether or not ... A) the device is safe to use with or do in. But ... B) taking into
consideration ... is there a support person. Their 65-year old mom who might be in good shape but ... cannot
necessarily offer maximum assistance if this person needs a significant amount of assistance ... we have to
have this conversation from the very beginning.
Participants reported that treatment goals typically focused on standing, stepping, and gait training. One
center selectively provides inpatients with 6 sessions of exoskeleton training. One therapist described his or
her approach:
Our current model that we are using in inpatient is they get six sessions ... patients love getting up
with the device, and then they kind of don't want to do anything else ... In an inpatient's world you
have a lot of other things that have to be addressed as well, so we have kind of a limited access to it.
A typical episode of outpatient exoskeleton therapy consists of 20 to 30 sessions. The minimum number of
staff involved in an exoskeleton therapy session across centers was 2, although on occasion more staff were
involved, depending on patients' needs.

Standardized assessments used across centers included the 10-m and 6-minute walk tests; individual centers
reported using a variety of balance, exertion, and manual motor tests to assess outcomes associated with
exoskeleton training.
Clinicians discussed the issues they consider when recommending various locomotor training strategies:
If I'm only able to do 10 minutes of gait training in a robot, and I can get 35 minutes in on a treadmill, I
think there is a dose difference there.
Clinicians discussed strategies to integrate exoskeletons into rehabilitation therapy services and the
motivational influence of exoskeletons. One clinician stated:
... that speaks volumes to motivating them to do a lot of their other functional tasks, because some of the
other goals they might not want to work on, but we can kind of use it as like a "carrot" and be like: "All right, if
you do this transfer, and work on this transfer this day, then by the end of the week we will be able to try to
get you up on the robot".... I think that has a big ... influence on a lot of other stuff we try to do.

Topic 2: Exoskeleton Benefits and Risks

Focus group participants identified a variety of perceived physiological, psychological, and social benefits and
risks associated with exoskeleton use (Table 4). In addition to improved gait while in the exoskeleton, they
related patient claims of improved cardiorespiratory function, reduced pain, improved bowel and bladder
function, and improved self-confidence and self-image. Therapists also identified several risks including fallrelated injuries, skin irritation, and high patient expectations. One participant commented regarding patients'
perceived benefits:
[Reduced] pain and spasticity seem to be the top two. We have had some folks talk about their bowel and
bladder, so it changes in how quickly they feel they can manage their bowel program. I had one person talk
about sensation changes in their bladder. But again, they were also getting a lot of other interventions at the
same time.
Another clinician added:
We've noticed changes in sensation in bowel and bladder for sure. So ability to either sense ... a full bladder, a
need to cath or to sense the bowel program.
Clinicians also perceived health and wellness benefits.
Dynamic weight bearing is beneficial for ... full health ... getting just up and out of their chairs in an upright
position. It's just for the cardiorespiratory function and also placing everything on the heart because a lot of
people will also end up getting that ... from ... dynamic weight bearing. And then ... one thing that definitely
should not be discounted is the psychosocial benefits, just being upright and feeling what it's like to walk
again.
Clinicians observed reductions in medication for spasticity and infections, saying:
We have seen people significantly reduce the amount of medications that they were taking, either it was for
spasm or for example, UTI. We had a couple of people when we did our big 40-person trial that had frequent
UTIs, and when they were up training with the exoskeleton, their UTI significantly went away. We followed up
a month later, and their UTI is back again.
Participants identified psychosocial benefits across all focus groups as a salient aspect of working with robotic
exoskeletons. For example, one clinician observed the motivating influence of exoskeleton use:
The ability that some feel that they can stand up ... and actually being told that they will never ever walk
again, and hearing that news, and here they are up walking, and they are like: "Can you videotape this? Can
you video it?" So, I think ... psychosocial[ly] ... this gives them that hope that ... "Someday I may be able to
walk again."

Another focus group participant observed:
If they feel like this [is] something that will make them get better, and stronger, and walk more and, ..., in a
better pattern, then they will give it a try and they will be willing to see what it has to offer for them.
Several therapists identified the psychosocial benefit of being upright and facing others eye-to-eye as a
reported benefit:
Feeling more engaged in social situations rather than ... being in a chair looking up and you can't really hear
what people are saying in a crowded room. That some of those psychological changes of ... being able to look
at people eye-to-eye. I know we hear that a lot, but it really is extremely important to our folks that are used
to being at chair level.
A common comment people say, "It's just nice to look someone in the eyes, and not be looking up at the
world."
Participants also described the critical role of patients' expectations, the risks of disappointment, and how
expectations change over time.
... The other thing that I think is really critical are patient expectations. I think in this room we are all 100
percent, it's about the patient, but we also have to be open and honest with them about how they can really
use these systems, and unless they come and try it, they won't know. We had a guy that wanted to purchase
one of the systems, and his goal was to get up and ... use it all day at work ... drive with it in his car and all of
that, and this was somebody that was part of our research program previously. And I don't know if he forgot
or what, but it was about almost a year between the end of research and when this individual chose to buy
one of the systems, and then when he came to try the system it was like: "Oh, well, I don't think I would use
this every day." ... They have this fantasy it's going to get rid of their wheelchair or whatever, and that's just
not the case, and that's another important aspect of giving patients a choice.
Participants noted the challenges patients encountered in seeking services to use an exoskeleton:
From a funding standpoint, it's very challenging for anybody to get funding to purchase one, and then to ...
find places where therapists are trained on how to use them, but then also be able to access them even if
they don't have that funding.
Another therapist noted the potential burden on volunteer caregivers using an exoskeleton:
One thing to also keep in mind is how taxing is it for the caregiver or the therapist to provide the assistance and
the training.
This comment contrasts with sources that anticipate reduced physical burden on caregivers and therapists
during training.19

Topic 3: Exoskeleton Preferences

Focus group participants identified several enhancements they would like to see in exoskeletons (Table 4).
Some patients also anticipate technology improvement, as one therapist noted:
He was still hesitant to purchase the [device] at this time. He was more interested in seeing what future technology
[may bring] ... maybe something a little bit less cumbersome, looking for something more streamlined. So he wants
his other equipment. I think he is just waiting for future technology.

DISCUSSION

Clinicians at each SCIMS center revealed similar practice patterns in terms of how they integrate robotic
exoskeletons into physical therapy services. All SCIMS centers adhere to manufacturers' and Food and Drug
Administration's (FDA's) guidance on device use but deploy exoskeletons in different settings and adopt different
clinical evaluations. This variability likely reflects both institutional culture and the minimal evidence from
randomized controlled trials and clinical studies to guide implementation and standardize practice
guidelines.5 Clinicians who deliver robotic exoskeleton therapy mostly include physical therapists with specialist

certification achieved through manufacturers' training. Many centers employ exercise specialists in addition to
physical and occupational therapists. ReWalk certifies individuals without a clinical background. While clinician
training and costs were not a focus of the focus group discussion guide, the costs associated with the delivery of
robotic exoskeleton therapy reflect clinicians' education and training, and therefore costs vary according to the
qualifications of the personnel who provide the training. Clinicians recognized the marketing value of offering
exoskeletons, noting that some patients sought out the collaborating facilities for physical therapy services because
they offered use of robotic exoskeletons. Therapists recognize that some patients who express interest in
exoskeletons may not meet the criteria for use of these devices. As with any intervention, therapists offer education
and guidance about approaches that are most appropriate to the patients' functional status, goals, and prognosis for
achieving those goals.
Clinicians identified a variety of secondary benefits from exoskeleton use. They observed psychological and
social benefits including satisfaction from making eye contact while standing to improved bladder and bowel
sensation and function, which allows greater ease in social activities. According to the clinicians, patients do
not voice secondary benefits as reasons for pursuing exoskeleton therapy, but many were pleased with these
benefits.
Clinicians observed that robotic exoskeleton technology continues to evolve rapidly, limiting their adoption of
devices to avoid early obsolescence. Although currently there are only 4 devices that are FDA approved, the
software and hardware of these devices have changed numerous times in the last decade, making standard
evaluations, fitting, and training difficult. To complicate issues further, the FDA will likely approve a dozen
new devices in the coming years. Thus, larger institutions are creating exoskeleton teams with therapists with
training, certification, and up-to-date information on the evolving rehabilitation robotics market.
Participants reported that patients voiced awareness of the pace of technological development as a
consideration in device purchases. For example, Shepherd Center's use of exoskeletons is evolving quickly as
its staff considers optimal and cost-effective ways to integrate them in therapy services. Ultimately, patient
demand for robotic exoskeletons motivates facilities to investigate purchase and use of this modality. For
example, TIRR Memorial Hermann provides access to exoskeleton use for inpatients so that they may try a
novel technology for overground walking that they might not have access to after discharge. Patients' ability
to purchase a personal mobility exoskeleton reflects a variety of considerations including individuals'
resources. Locomotor training with exoskeletons also increased rapidly during the course of this study, with
the AbilityLab reporting considerable growth of device use after moving to a new facility with expanded
inpatient, outpatient, and home training clinics.
Several study design features limit the generalizability of the findings. Results reflect the experience of only 4
centers, all of which are part of the SCIMS; they may not be representative of all hospitals providing SCI
rehabilitation nationally. Clinicians had the opportunity to decline study participation, though nearly all
clinicians involved in robotic exoskeleton service delivery participated. Despite efforts to create a
nonevaluative climate, the group format may have limited their willingness to voice opinions that conflicted
with leadership and peer perspectives.
This study focused on therapists' perspectives due to their unique understanding and skill with exoskeleton
use and physical functioning. Future studies should seek patients' perspectives in device selection and
evaluation. We need a fuller understanding of the individual-, facility-, and societal-level costs and benefits
associated with robotic exoskeleton use in clinical and wellness applications.

CONCLUSIONS

This study provides insight into the issues facilities face and the considerations clinicians use in delivering
robotic exoskeleton therapy and extends our knowledge of users' perspectives.20 The 4 SCIMS centers
involved in the study have similar practice patterns in terms of how they integrate overground robotic
exoskeletons into physical therapy services. While they adhere to manufacturers' and FDA's guidance on
device use, only 1 study center deploys exoskeletons during inpatient rehabilitation currently. Clinicians at all

study centers described patients' report of bowel, bladder, and psychosocial benefits in addition to improved
gait. The study centers educate patients on rapid technology development when they recommend devices to
patients contemplating purchases for personal mobility. An unintended effect of these devices may be to
engage patients more fully in their rehabilitation quite apart from walking or promoting neuromotor recovery
by offering hope when patients struggle to see a positive future. There is currently little evidence to guide and
standardize the integration of exoskeletons into rehabilitation therapy services and a pressing need to
generate evidence to guide practice and to inform patients' expectations. A valuable next step would be to
convene a technical expert panel to draft consensus guidelines on device use. Clinics considering use of
robotic exoskeletons should define the therapy goals that are amenable to the hardware and software
capabilities of specific exoskeletons; select patients who are likely to benefit from exoskeleton therapy based
on institutional pilot testing, early studies, and manufacturers' guidelines; and develop strategies to ensure
that patient expectations are realistic to obtain maximum benefit for therapy and personal mobility. Based on
SCIMS Centers' experience, we recommend that facilities sites.
1. complete training recommended by device manufacturers;
2. become familiar with indications and contraindications for specific devices;
3. adjust goals and protocols to individual patient's circumstances and needs;
4. notify manufacturers of device malfunctions or repair needs;
5. maximize patients' contributions by weaning them slowly off the motors progressively;
6. monitor skin at all areas that contact the device before and after use;
7. encourage users to provide feedback while using the device and adjust device settings accordingly;
8. progress through a device's modes to facilitate learning and achieve specific goals;
9. apply gait training strategies with application of frequency, intensity, time, and type (FITT) principle to use
the device effectively and optimize patients' outcomes; and
10. monitor patients' cardiovascular, integumentary, and neuromuscular responses to exoskeleton sessions.
We recommend that facilities not
1. use devices with patients who have open skin lesions or wounds in the areas that contact the exoskeleton;
2. use an exoskeleton device with a patient who is uncomfortable with the technology;
3. assume that the device will prevent falls-continue to use usual guarding techniques;
4. force the fit of the device. If a patient's fit is borderline, err on the side of caution; and
5. use the same software program in an exoskeleton for all patients.
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APPENDIX Focus Group Discussion Guide for Therapists With Robotic Exoskeleton
Experience

1. How do you use robotic exoskeletons in your practice?
a. What criteria do you use to select patients with SCI for exoskeletons use?
b. What latitude do you have in selecting patients for exoskeletons use?
c. What makes/models do you use?
d. Why do you use these models?
e. What kinds of modifications would you like to have made to robotic exoskeletons? Why?
f. How many clinicians are present when a patient is learning to use a robotic exoskeleton? If any, are they therapists? Aides?
What are their qualifications?
g. What does a typical exoskeleton therapy session look like? What's the breakdown of time spent on what activities. (If the
answer is "it depends"-ask) It depends on what? Please give an example.

h. Would you use the same number of therapists and aides for conventional therapy for the patient who uses an exoskeleton
based on the answer to the previous question?
2. What standardized assessments do you use to assess patients' progress using an exoskeleton?
3. Do you work with patients who use exoskeletons in the community?
a. What motivates patients to use exoskeletons in the community?
b. What facilitates their use of exoskeletons in the community?
c. What limits their use of exoskeletons in the community?
d. What risks have patients experienced using exoskeletons in the community?
e. What risks are you concerned about?
4. What benefits do patients receive from exoskeletons use in the clinic?
a. What kinds of physical benefits?
b. What about social benefits?
c. What about occupational benefits?
d. Any emotional benefits?
e. Any other benefits?
5. What risks or harm have patients experienced using an exoskeleton?
a. What kinds of physical harms?
b. What about social harms?
c. What about occupational harms?
d. Any emotional harms?
e. Any other harms?
6. What aspects of the device, patient, or environment facilitate benefit?
a. Patient characteristics?
b. Device characteristics?
c. Environmental characteristics?
7. What aspects of the device, patient, or environment limit device benefit?
a. Patient characteristics?
b. Device characteristics?
c. Environmental characteristics?
8. Have any of your patients purchased exoskeletons?
a. What kinds of patients?
b. What kinds of devices?
c. What kinds of activities?
9. What other aspects of exoskeleton use or therapy that we have not discussed would you like to mention or add?

